piperidines and Primary-Immunodeficiency-Diseases

Patients with immunocompromised disorders have mainly been excluded from clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial was to investigate safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls.. 539 study subjects (449 patients and 90 controls) were included. The patients had either primary (n=90), or secondary immunodeficiency disorders due to human immunodeficiency virus infection (n=90), allogeneic hematopoietic stem cell transplantation/CAR T cell therapy (n=90), solid organ transplantation (SOT) (n=89), or chronic lymphocytic leukemia (CLL) (n=90). The primary endpoint was seroconversion rate two weeks after the second dose. The secondary endpoints were safety and documented SARS-CoV-2 infection.. Adverse events were generally mild, but one case of fatal suspected unexpected serious adverse reaction occurred. 72.2% of the immunocompromised patients seroconverted compared to 100% of the controls (p=0.004). Lowest seroconversion rates were found in the SOT (43.4%) and CLL (63.3%) patient groups with observed negative impact of treatment with mycophenolate mofetil and ibrutinib, respectively.. The results showed that the mRNA BNT162b2 vaccine was safe in immunocompromised patients. Rate of seroconversion was substantially lower than in healthy controls, with a wide range of rates and antibody titres among predefined patient groups and subgroups. This clinical trial highlights the need for additional vaccine doses in certain immunocompromised patient groups to improve immunity.. Knut and Alice Wallenberg Foundation, the Swedish Research Council, Nordstjernan AB, Region Stockholm, Karolinska Institutet, and organizations for PID/CLL-patients in Sweden.

Topics: Adenine; Antibodies, Viral; BNT162 Vaccine; COVID-19; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunogenicity, Vaccine; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycophenolic Acid; Organ Transplantation; Piperidines; Primary Immunodeficiency Diseases; Prospective Studies; SARS-CoV-2; Seroconversion; Spike Glycoprotein, Coronavirus; Vaccination; Vaccine Efficacy

Genetic testing has increased the number of variants identified in disease genes, but the diagnostic utility is limited by lack of understanding variant function. CARD11 encodes an adaptor protein that expresses dominant-negative and gain-of-function variants associated with distinct immunodeficiencies. Here, we used a "cloning-free" saturation genome editing approach in a diploid cell line to simultaneously score 2,542 variants for decreased or increased function in the region of CARD11 associated with immunodeficiency. We also described an exon-skipping mechanism for CARD11 dominant-negative activity. The classification of reported clinical variants was sensitive (94.6%) and specific (88.9%), which rendered the data immediately useful for interpretation of seven coding and splicing variants implicated in immunodeficiency found in our clinic. This approach is generalizable for variant interpretation in many other clinically actionable genes, in any relevant cell type.

Topics: Adenine; B-Cell CLL-Lymphoma 10 Protein; B-Lymphocytes; CARD Signaling Adaptor Proteins; Cell Line; Diploidy; Exons; Genes, Dominant; Genetic Variation; Guanylate Cyclase; Humans; Immunologic Deficiency Syndromes; Jurkat Cells; Lymphoma; NF-kappa B p50 Subunit; Piperidines; Polymorphism, Single Nucleotide; Primary Immunodeficiency Diseases; Sensitivity and Specificity